IVVD stock icon

Invivyd
IVVD

$1.21
2.36%
 

About: Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Employees: 95

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
0
News positive %
of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

3,754% more call options, than puts

Call options by funds: $4.01M | Put options by funds: $104K

540% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 5

46% more capital invested

Capital invested by funds: $220M [Q4 2023] → $321M (+$101M) [Q1 2024]

46% more funds holding

Funds holding: 59 [Q4 2023] → 86 (+27) [Q1 2024]

39% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 18

15.06% more ownership

Funds ownership: 50.66% [Q4 2023] → 65.72% (+15.06%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$9
644%
upside
Avg. target
$13.17
988%
upside
High target
$15
1,140%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
1,140%upside
$15
Buy
Reiterated
24 May 2024
HC Wainwright & Co.
Patrick Trucchio
1,140%upside
$15
Buy
Reiterated
14 May 2024
Guggenheim
Evan Wang
644%upside
$9
Buy
Upgraded
5 Apr 2024
Morgan Stanley
Maxwell Skor
726%upside
$10
Overweight
Upgraded
26 Mar 2024
HC Wainwright & Co.
Patrick Trucchio
1,140%upside
$15
Buy
Reiterated
25 Mar 2024

Financial journalist opinion

Based on 5 articles about IVVD published over the past 30 days